The present Competitive Intelligence Report about Targeted Therapy of
Hepatitis C provides a competitor evaluation in the field of specifically
targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011.
Purchase of the downloadable pdf report includes a 6-month online access to
the data of the report and any updates since the publication date. Credentials
to access the database will be sent by e-mail and allow online work with the
project data to print or export an individual report.
Most hepatitis C virus (HCV) infected individuals seeking treatment are
chronically infected. Treatment goal is to achieve a sustained virological
response (SVR), which is the absence of serum HCV RNA up to 6 months after
therapy is concluded. To increase efficiency of interferon treatment,
pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with
ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted
in a further increase in treatment efficiency with 54% of HCV infected
patients achieving SVR. The response and rate of SVR is dependent on the
genotype of HCV with only 30% of genotype 1 infected individuals achieving
SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination
therapy. Combination therapy treatment regiments are genotype dependent and
the amount of peg-IFN-α administered is dependent on the type used.
The suboptimal response has led to a shift in the investigational focus for
treatment of HCV toward specifically targeted antiviral therapy for HCV
agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with
frequent side effects and have a negative impact on the patient' s quality of
life.
The report includes a compilation of current active projects in research and
development of molecules specifically directed against novel targets in
hepatitis C. In addition, the report lists company-specific R&D pipelines of
targeted therapeutics in hepatitis C. Competitor projects are listed in a
tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
HCV Protease Inhibitors
HCV RNA Polymerase Inhibitors
Cyclophilin Inhibitors
HCV NS5A Protein Inhibitors
HCV NS4B-RNA Binding Inhibitors
Therapeutic & Preventative HCV Vaccines
Therapeutic HCV Antibodies
HCV Viral Entry Inhibitors
HCV Replication Inhibitors
Novel Mechanism of Action HCV Virus & Host Cell Targets
TLR Agonists
Various
Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
About La Merie
Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
Abbott
Achillion Pharmaceuticals
Alios Biopharma
Altor Biosciences
Anadys Pharmaceuticals
Astex Therapeutics
Avila Therapeutics
Bionor Immuno
Biotica Technology
Biotron
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
C-Pharma
Can-Fite BioPharma
Chimerix
ChronTech Pharma
Compass Biotechnologies
Conatus Pharmaceuticals
CureTech
Cytheris
Debiopharm
Dynavax Technologies
Eiger Pharmaceuticals
Enanta Pharmaceuticals
Epiphany Biosciences
Epixis
Genmab
GenPhar
Gilead Sciences
GlaxoSmithKline (GSK)
GlobeImmune
Heat Biologics
Idenix Pharmaceuticals
Idera Pharmaceuticals
Inhibitex
Inovio
Intellektualniy Dialog
Intercell
iTherX Pharmaceuticals
Japan Tobacco
Johnson & Johnson (J&J)
Medivir
Massachusetts Biologic Laboratories (MBL)
Merck & Co
Mitsubishi Tanabe Pharma
Morningside Asia Venture
Novartis
Okairos
Ono Pharmaceutical
Paladin Biosciences
Peregrine Pharmaceuticals
Pfizer
Pharmasset
PTC Therapeutics
Presidio Pharmaceuticals
Progenics Pharmaceuticals
Regulus Therapeutics
Replicor
Roche
Rosetta Genomics
Samaritan Pharmaceuticals
Santaris Pharma
SCYNEXIS
Tacere Therapeutics
TaiGen Biotechnology
Teva Pharmaceutical Industries
Theravance
Transgene
Tripep
Vertex Pharmaceuticals
Viriome
Virionics
ViroBay
Table of Contents
Table of Contents
1. Targeted Therapy of Hepatitis C
HCV Protease Inhibitors
HCV RNA Polymerase Inhibitors
Cyclophilin Inhibitors
HCV NS5A Protein Inhibitors
HCV NS4B-RNA Binding Inhibitors
Therapeutic & Preventative HCV Vaccines
Therapeutic HCV Antibodies
HCV Viral Entry Inhibitors
HCV Replication Inhibitors
Novel Mechanism of Action HCV Virus & Host Cell Targets
TLR Agonists
Various
2. Corporate Targeted Therapy of Hepatitis C R&D
Pipelines
Abbott
Achillion Pharmaceuticals
Alios Biopharma
Altor Biosciences
Anadys Pharmaceuticals
Astex Therapeutics
Competitor Analysis
Avila Therapeutics
Bionor Immuno
Biotica Technology
Biotron
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
C-Pharma
Can-Fite BioPharma
Chimerix
ChronTech Pharma
Compass Biotechnologies
Conatus Pharmaceuticals
CureTech
Cytheris
Debiopharm
Dynavax Technologies
Eiger Pharmaceuticals
Enanta Pharmaceuticals
Epiphany Biosciences
Epixis
Genmab
GenPhar
Gilead Sciences
GlaxoSmithKline (GSK)
GlobeImmune
Heat Biologics
Idenix Pharmaceuticals
Idera Pharmaceuticals
Inhibitex
Inovio
Intellektualniy Dialog
Intercell
iTherX Pharmaceuticals
Japan Tobacco
Johnson & Johnson (J&J)
Medivir
Massachusetts Biologic Laboratories (MBL)
Merck & Co
Mitsubishi Tanabe Pharma
Morningside Asia Venture
Novartis
Okairos
Ono Pharmaceutical
Paladin Biosciences
Peregrine Pharmaceuticals
Pfizer
Pharmasset
PTC Therapeutics
Presidio Pharmaceuticals
Progenics Pharmaceuticals
Regulus Therapeutics
Replicor
Roche
Rosetta Genomics
Samaritan Pharmaceuticals
Santaris Pharma
SCYNEXIS
Tacere Therapeutics
TaiGen Biotechnology
Teva Pharmaceutical Industries
Theravance
Transgene
Tripep
Vertex Pharmaceuticals
Viriome
Virionics
ViroBay
Competitor Analysis: Targeted Therapy of Hepatitis C published by La Merie Publishing in August 31, 2011. This report consists of 91 Pages and the price starts from US $ 826.
The contents of this page may be different from the latest version. Please contact us for details.
